This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

MorphoSys 将来の成長

Future 基準チェック /26

MorphoSys利益と収益がそれぞれ年間59.1%と25%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に7.7% 78.2%なると予測されています。

主要情報

59.1%

収益成長率

78.2%

EPS成長率

Biotechs 収益成長	37.0%
収益成長率	25.0%
将来の株主資本利益率	7.7%
アナリストカバレッジ	Good
最終更新日	05 Aug 2024

今後の成長に関する最新情報

Recent updates

業績と収益の成長予測

LSE:0NDV - アナリストの将来予測と過去の財務データ ( )EUR Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	425	-78	-120	-50	5
12/31/2025	322	-140	-236	-201	8
12/31/2024	180	-249	-296	-253	3
3/31/2024	241	-469	-286	-284	N/A
12/31/2023	238	-190	-299	-296	N/A
9/30/2023	223	104	-363	-355	N/A
6/30/2023	255	100	-349	-338	N/A
3/31/2023	261	-61	-321	-306	N/A
12/31/2022	278	-151	-382	-367	N/A
9/30/2022	250	-861	-436	-417	N/A
6/30/2022	195	-851	-606	-588	N/A
3/31/2022	174	-596	-610	-583	N/A
12/31/2021	180	-514	-508	-481	N/A
9/30/2021	163	-150	-423	-393	N/A
6/30/2021	143	-103	-295	-246	N/A
3/31/2021	124	-177	-255	-217	N/A
12/31/2020	328	98	-14	35	N/A
9/30/2020	303	64	26	63	N/A
6/30/2020	293	105	98	113	N/A
3/31/2020	309	153	137	152	N/A
12/31/2019	72	-103	-85	-81	N/A
9/30/2019	71	-96	-68	-64	N/A
6/30/2019	114	-42	-42	-39	N/A
3/31/2019	87	-59	-33	-31	N/A
12/31/2018	76	-56	-35	-33	N/A
9/30/2018	94	-27	-16	-14	N/A
6/30/2018	54	-82	-61	-48	N/A
3/31/2018	58	-74	-68	-55	N/A
12/31/2017	67	-70	N/A	-38	N/A
9/30/2017	52	-84	N/A	-52	N/A
6/30/2017	49	-73	N/A	-59	N/A
3/31/2017	49	-68	N/A	-47	N/A
12/31/2016	50	-60	N/A	-47	N/A
9/30/2016	49	-45	N/A	-48	N/A
6/30/2016	48	-40	N/A	-41	N/A
3/31/2016	48	-33	N/A	-35	N/A
12/31/2015	106	15	N/A	-24	N/A
9/30/2015	111	27	N/A	-15	N/A
6/30/2015	116	33	N/A	-3	N/A
3/31/2015	119	37	N/A	-4	N/A
12/31/2014	64	-3	N/A	-14	N/A
9/30/2014	61	-6	N/A	-15	N/A
6/30/2014	60	-5	N/A	79	N/A
3/31/2014	77	7	N/A	76	N/A
12/31/2013	78	7	N/A	89	N/A
9/30/2013	80	14	N/A	100	N/A

アナリストによる今後の成長予測

収入対貯蓄率: 0NDV今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: 0NDV今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: 0NDV今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: 0NDVの収益 ( 25% ) UK市場 ( 3.5% ) よりも速いペースで成長すると予測されています。

高い収益成長: 0NDVの収益 ( 25% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: 0NDVの自己資本利益率は、3年後には低くなると予測されています ( 7.7 %)。

This company listing is no longer active

MorphoSys 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

MorphoSys AG Provides Sales Guidance for the Financial Year 2024

Morphosys AG Provides Earnings Guidance for the Year 2023

MorphoSys AG Provides Earnings Guidance for the Year 2023

Morphosys Ag Provides Sales Guidance for the Financial Year 2023

Morphosys Ag Revises Monjuvi U.S. Net Product Sales Guidance for the Full Year of 2022

Morphosys Ag Updates Monjuvi U.S. Net Product Sales Guidance for the Year 2022

Recent updates

MorphoSys Completes Voluntary Delisting from the Frankfurt Stock Exchange and Nasdaq Global Market

MorphoSys AG, Annual General Meeting, Aug 27, 2024

MorphoSys Announces Voluntary Delisting from the Nasdaq Global Market

MorphoSys AG to Report Q2, 2024 Results on Aug 29, 2024

MorphoSys AG(XTRA:MOR) dropped from Germany MDAX Index (Performance)

MorphoSys AG(XTRA:MOR) dropped from Germany TECDAX (Total Return) Index

MorphoSys AG Announces Board Changes

Novartis Continues to Progress the Workstreams for Implementation of a Delisting of MorphoSys

Novartis Continues to Progress the Workstreams for Implementation of a Delisting of MorphoSys

New major risk - Negative shareholders equity

New major risk - Financial position

New minor risk - Profitability

Full year 2023 earnings released: €5.53 loss per share (vs €4.42 loss in FY 2022)

Novartis data42 AG entered into an agreement to make a voluntary public takeover offer to acquire MorphoSys AG (XTRA:MOR) for €2.3 billion.

Novartis data42 AG entered into an agreement to make a voluntary public takeover offer to acquire MorphoSys AG (XTRA:MOR) for €2.3 billion.

MorphoSys AG Provides Sales Guidance for the Financial Year 2024

Investor sentiment improves as stock rises 20%

Investor sentiment deteriorates as stock falls 15%

New minor risk - Shareholder dilution

MorphoSys AG to Report First Half, 2024 Results on Aug 07, 2024

MorphoSys AG has filed a Follow-on Equity Offering in the amount of €102.69582 million.

MorphoSys AG to Report Fiscal Year 2023 Results on Mar 13, 2024

MorphoSys AG’ Pelabresib Improves All Four Hallmarks of Myelofibrosis in Phase 3 MANIFEST-2 Study

Investor sentiment improves as stock rises 31%

MorphoSys AG Announces Strong Topline Results from the Phase 3 MANIFEST-2 Study Investigating Pelabresib

New major risk - Financial position

New minor risk - Share price stability

Third quarter 2023 earnings released: €3.50 loss per share (vs €3.60 loss in 3Q 2022)

Investor sentiment deteriorates as stock falls 17%

MorphoSys AG to Showcase Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2023 ASH Annual Meeting

Investor sentiment improves as stock rises 16%

Morphosys AG Provides Earnings Guidance for the Year 2023

Investor sentiment deteriorates as stock falls 18%

Zoetis Inc. (NYSE:ZTS) acquired adivo GmbH from founders, High-Tech Gründerfonds, the Swiss Occident Group AG and MorphoSys AG (XTRA:MOR).

MorphoSys Receives U.S. FDA Fast Track Designation for Tulmimetostat in Endometrial Cancer

MorphoSys AG Provides Earnings Guidance for the Year 2023

New major risk - Revenue and earnings growth

Second quarter 2023 earnings released: €2.16 loss per share (vs €6.88 loss in 2Q 2022)

New minor risk - Share price stability

Morphosys Ag Provides Sales Guidance for the Financial Year 2023

First quarter 2023 earnings released: €1.30 loss per share (vs €3.59 loss in 1Q 2022)

Full year 2022 earnings released: €4.42 loss per share (vs €15.40 loss in FY 2021)

MorphoSys AG Expects Topline Data from Phase 3 Study of Pelabresib in Myelofibrosis in Early 2024

MorphoSys AG Announces Sung Lee, Chief Financial Officer Decided to Leave

Morphosys Presents New Longer-Term Phase 2 Results on Pelabresib in Myelofibrosis, Including Potential Disease-Modifying Activity At Ash 2022

MorphoSys AG, Annual General Meeting, May 17, 2023

Third quarter 2022 earnings released: €3.60 loss per share (vs €3.30 loss in 3Q 2021)

MorphoSys AG Presents Preliminary Results from Phase 1/2 Study of Tulmimetostat (CPI-0209)

Morphosys Ag Revises Monjuvi U.S. Net Product Sales Guidance for the Full Year of 2022

MorphoSys AG Announces Executive Changes

Second quarter 2022 earnings released: €6.88 loss per share (vs €0.64 profit in 2Q 2021)

Morphosys Ag Updates Monjuvi U.S. Net Product Sales Guidance for the Year 2022

MorphoSys AG Confirms Financial Guidance for the Year 2022

MorphoSys AG Announces Supervisory Board Changes

First quarter 2022 earnings released: €3.59 loss per share (vs €1.27 loss in 1Q 2021)

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

MorphoSys Presents Latest Data from the Phase 2 Manifest Study Evaluating the Potential of Pelabresib in the Treatment of Myelofibrosis

MorphoSys and Incyte Announce Additional Real-World Evidence Results from RE-MIND2 Study of Tafasitamab (Monjuvi®) in Combination with Lenalidomide for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Third quarter 2021 earnings released: €3.30 loss per share (vs €2.00 loss in 3Q 2020)

Health Canada Grants Marketing Authorization for Minjuvi® (Tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Second quarter 2021 earnings released: EPS €0.64 (vs €1.62 loss in 2Q 2020)

MorphoSys AG (XTRA:MOR) completed the acquisition of Constellation Pharmaceuticals, Inc. (NasdaqGS:CNST).

Incyte and MorphoSys Announce Positive CHMP Opinion for Tafasitamab in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

MorphoSys to Present Data on Tafasitamab (Monjuvi(R)) at the 2021 ASCO Annual Meeting

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率